Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Immunotherapy
/ methods
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Prognosis
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Retrospective Studies
Survival Rate
Antibiotics
gut microbiota
immune checkpoint inhibitors
non-small cell lung cancer
survival
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
29
07
2021
revised:
22
08
2021
accepted:
23
08
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
13
10
2021
Statut:
ppublish
Résumé
There is an increasing use of immunotherapy for non-small cell lung cancer (NSCLC) patients. The present study analysed the effect of antibiotic use on the outcome of NSCLC patients undergoing treatment with anti-programmed cell death-1 (anti-PD-1) immunotherapy. This was a retrospective study of 69 NSCLC patients. Eighteen out of 69 patients received antibiotics within 21 days before or within 21 days after start of anti-PD-1 therapy. Patients treated with anti-PD-1 antibodies receiving antibiotics had greatly decreased objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) compared to those who did not use antibiotics. Multivariate analysis showed that antibiotic treatment of patients on anti-PD-1 antibody therapy was an independent negative predictive factor of PFS; however, it was not a significant independent predictive factor of OS. Use of antibiotics within 21 days before and after anti-PD-1 treatment initiation in patients with NSCLC strongly reduced OS and PFS, suggesting the two treatments should not be combined.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
There is an increasing use of immunotherapy for non-small cell lung cancer (NSCLC) patients. The present study analysed the effect of antibiotic use on the outcome of NSCLC patients undergoing treatment with anti-programmed cell death-1 (anti-PD-1) immunotherapy.
PATIENTS AND METHODS
METHODS
This was a retrospective study of 69 NSCLC patients. Eighteen out of 69 patients received antibiotics within 21 days before or within 21 days after start of anti-PD-1 therapy.
RESULTS
RESULTS
Patients treated with anti-PD-1 antibodies receiving antibiotics had greatly decreased objective response rate (ORR), overall survival (OS) and progression-free survival (PFS) compared to those who did not use antibiotics. Multivariate analysis showed that antibiotic treatment of patients on anti-PD-1 antibody therapy was an independent negative predictive factor of PFS; however, it was not a significant independent predictive factor of OS.
CONCLUSION
CONCLUSIONS
Use of antibiotics within 21 days before and after anti-PD-1 treatment initiation in patients with NSCLC strongly reduced OS and PFS, suggesting the two treatments should not be combined.
Identifiants
pubmed: 34593446
pii: 41/10/4985
doi: 10.21873/anticanres.15312
doi:
Substances chimiques
Anti-Bacterial Agents
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4985-4993Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.